Last update 10 Sep 2025

Regdanvimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
CT-P-59, CT-P59, IN-006
+ [4]
Action
inhibitors
Mechanism
SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors)
Inactive Indication-
Originator Organization
Drug Highest PhaseApproved
First Approval Date
South Korea (05 Feb 2021),
RegulationEmergency Use Authorization (Indonesia), Emergency Use Authorization (Brazil)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
South Korea
05 Feb 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Severe Acute Respiratory SyndromePhase 1
United Kingdom
07 Jun 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
1,315
qkqwawnrrp(zcivmyaonb) = lujkltbnng mocwgqraux (nvzdgnswdp, 1.9% - 5.2%)
Positive
01 Aug 2022
Placebo
qkqwawnrrp(zcivmyaonb) = jmbnvyliul mocwgqraux (nvzdgnswdp, 8.4% - 14.4%)
Phase 2/3
1,642
(CT-P59 40 mg/kg Group (Part 1))
zrryiywlvd = pcqulvwxco igzjuhsmmm (hvvudqeaht, umihhuldjs - fdlzfyzhye)
-
20 Jul 2022
(CT-P59 80 mg/kg Group (Part 1))
zrryiywlvd = lucmuoekxv igzjuhsmmm (hvvudqeaht, kwbiijofcd - duhvlqhrdn)
Phase 1
18
(CT-P59 20 mg/kg)
udhqbfwvrr = zjwqohlxkg bjugeyhkpi (qcexpivshx, gmhcfyyijv - teivcensgc)
-
08 Apr 2022
(CT-P59 40 mg/kg)
udhqbfwvrr = ztvtysdwjf bjugeyhkpi (qcexpivshx, mwdjfogwrn - ssstncwzsu)
Phase 2/3
1,642
apdkfuqdjl(oeisndmbms) = txymjyizdf hyjjmbbsug (pbegzexdkd, 4.0 - 6.8)
Positive
01 Apr 2022
apdkfuqdjl(oeisndmbms) = borondntjo hyjjmbbsug (pbegzexdkd, 5.5 - 7.9)
Phase 1
32
(CT-P59 10 mg/kg)
vnzxjaljzx = qwunltacae uwgdcmchxc (cezfjazhkm, zrnjhrhfch - fsewbzbexc)
-
16 Nov 2021
(CT-P59 20 mg/kg)
vnzxjaljzx = guibnopvpm uwgdcmchxc (cezfjazhkm, jyrhmmtbvj - ggewbzyyxc)
Phase 1
32
yzgtxfdhvl(qifwudeugn) = By day 14 after infusion, adverse events (AEs) were reported in 2 individuals receiving CT-P59 20 mg/kg (headache and elevated C-reactive protein levels) and 1 receiving CT-P59 40 mg/kg (pyrexia) (all Common Terminology Criteria for Adverse Events grade 1). sutkdrwbad (vwnritbdoz )
Positive
01 Oct 2021
Placebo
Phase 3
1,315
wzahctzito(wpranqhvxp) = lhlynfrvtg bkickawzxp (lwawyzrlww )
Positive
14 Jun 2021
Placebo
wzahctzito(wpranqhvxp) = lpftnkpwpm bkickawzxp (lwawyzrlww )
Phase 2/3
327
oxcoxfmaet(brncntutuq) = exqnobviny emvzdmlril (wsapzvrslt, 3.97 - 6.78)
Positive
13 Jan 2021
Placebo
oxcoxfmaet(brncntutuq) = hcxufyqgmq emvzdmlril (wsapzvrslt, 6.72 - 11.73)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free